Abstract
Identification of the smallest antibody fragment still capable of binding to antigen has progressed from full antibody molecules to Fab and recombinant single chain Fv fragments. Now, a further reduction to single domain binding proteins based upon immunoglobulin VH and VH-like domains offers exciting prospects in the development of novel immunotherapeutics and immunodiagnostics. Minimisation of the antigen-binding fragment to such small single-domain proteins offers the advantages of enhanced stability, and possibly access to a class of antigenic epitopes not generally recognised by conventional antibodies.
Keywords: Immunoglobulin VH Domains, Fv fragments, Recombinant single chain, Natural VH Domains, Camelidae, Camelisation
Current Pharmaceutical Biotechnology
Title: Immunoglobulin VH Domains and Beyond Design and Selection of Single-Domain Binding and Targeting Reagents
Volume: 1 Issue: 3
Author(s): S. D. Nuttall, R. A. Iring and P. J. Hudson
Affiliation:
Keywords: Immunoglobulin VH Domains, Fv fragments, Recombinant single chain, Natural VH Domains, Camelidae, Camelisation
Abstract: Identification of the smallest antibody fragment still capable of binding to antigen has progressed from full antibody molecules to Fab and recombinant single chain Fv fragments. Now, a further reduction to single domain binding proteins based upon immunoglobulin VH and VH-like domains offers exciting prospects in the development of novel immunotherapeutics and immunodiagnostics. Minimisation of the antigen-binding fragment to such small single-domain proteins offers the advantages of enhanced stability, and possibly access to a class of antigenic epitopes not generally recognised by conventional antibodies.
Export Options
About this article
Cite this article as:
Nuttall D. S., Iring A. R. and Hudson J. P., Immunoglobulin VH Domains and Beyond Design and Selection of Single-Domain Binding and Targeting Reagents, Current Pharmaceutical Biotechnology 2000; 1 (3) . https://dx.doi.org/10.2174/1389201003378906
DOI https://dx.doi.org/10.2174/1389201003378906 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Biodefense Properties of Milk: The Role of Antimicrobial Proteins and Peptides
Current Pharmaceutical Design Editorial: Oncolytic Virus and Gene Thearapy Application: Update 2018
Current Cancer Drug Targets Radiolabeled Oligonucleotides for Antisense Imaging
Current Organic Synthesis Recent Advances in the Use of Metallic Nanoparticles with Antitumoral Action - Review
Current Medicinal Chemistry Meet Our Editorial Board Member:
Current Medicinal Chemistry Targeting Blood Vessels for the Treatment of Non-Small Cell Lung Cancer
Current Cancer Drug Targets Gender Differences in Ischemic Heart Disease
Recent Patents on Cardiovascular Drug Discovery Tropism-Modified Adenoviral and Adeno-Associated Viral Vectors for Gene Therapy
Current Gene Therapy Morpho-Functional Features of In-Vitro Cell Death Induced by Physical Agents
Current Pharmaceutical Design Involvement of the Toxic AGEs (TAGE)-RAGE System in the Pathogenesis of Diabetic Vascular Complications: A Novel Therapeutic Strategy
Current Drug Targets PP2A in the Regulation of Cell Motility and Invasion
Current Protein & Peptide Science Tocilizumab Labeling with 99mTechnetium via HYNIC as a Molecular Diagnostic Agent for Multiple Myeloma
Anti-Cancer Agents in Medicinal Chemistry Xenicane Natural Products: Biological Activity and Total Synthesis
Current Pharmaceutical Design Drug Discovery and the Impact of the Safe Harbor Provision of the Hatch-Waxman Act
Current Topics in Medicinal Chemistry Compounds From Celastraceae Targeting Cancer Pathways and Their Potential Application in Head and Neck Squamous Cell Carcinoma: A Review
Current Genomics High-Level Secretory Expression and Purification of Recombinant Human Interleukin 1 Beta in Pichia pastoris
Protein & Peptide Letters Synthesis and Biological Evaluation of Licofelone Derivatives as Anticancer and Anti-inflammatory Agents
Letters in Drug Design & Discovery Radiolabelled Peptides: Eon in Radiopharmaceutical
Current Radiopharmaceuticals Inhibition of RET Activated Pathways: Novel Strategies for Therapeutic Intervention in Human Cancers
Current Pharmaceutical Design Chios Gum Mastic: A Review of its Biological Activities
Current Medicinal Chemistry